LNTH Lantheus Holdings Inc

P/E 25.4
Forward P/E 14.58
Price/Sales 4.274
Beta 0.025
Div Yield --
Market Cap --

Company Analysis

Latest News

Steve Cohen's Point72 Exits $70M Stake in Lantheus Holdings

Steven Cohen's Point72 Asset Management has liquidated its entire position in Lantheus Holdings (LNTH), according to its latest quarterly disclosure. The firm...

Deerfield Management Exits $83.5M Position in Lantheus Holdings

Major healthcare investment firm Deerfield Management has fully exited its position in Lantheus Holdings (LNTH), a company focused on diagnostic imaging...

Lantheus Reports Positive Alzheimer's Imaging Results in Two Phase 3 TAUKLARIFY Studies

Lantheus Reports Positive Alzheimer's Imaging Results in Two Phase 3 TAUKLARIFY Studies

Lantheus Holdings announced positive results from two pivotal Phase 3 studies of TAUKLARIFY™ (florquinitau F 18 injection), a PET imaging agent. Presented at...

Lantheus to Sell CDMO Business to PharmaLogic and Secure Long-Term Supply Deal

Lantheus to Sell CDMO Business to PharmaLogic and Secure Long-Term Supply Deal

Lantheus Holdings, Inc. announced a definitive agreement to sell its contract development and manufacturing organization (CDMO) business, including its...

Lantheus Holdings Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026

Lantheus Holdings Inc is expected to report Q3 2026 revenue of $360.82 million and earnings per share of $1.01, with its stock currently trading at $100.46...

Lantheus Merger with Curium Faces Extended FTC Antitrust Review After Second Request

Lantheus Merger with Curium Faces Extended FTC Antitrust Review After Second Request

Lantheus Holdings announced that both it and Curium US Holdings have received a request for additional information (a "Second Request") from the U.S. Federal...

Lantheus Stockholders Approve Merger with Curium US Holdings LLC

Lantheus Stockholders Approve Merger with Curium US Holdings LLC

Lantheus Holdings announced that its stockholders have approved the previously disclosed merger agreement under which the company will be acquired by Curium US...

🔴 Lantheus is trading 5% down in pre-market

Lantheus is trading at $95.00, down 4.96% in pre-market; no verified report identifies a specific catalyst for the decline. - A recent SEC filing disclosed...

Lantheus Issues Supplemental Disclosures for Merger Amid Shareholder Lawsuits

Lantheus Issues Supplemental Disclosures for Merger Amid Shareholder Lawsuits

Lantheus Holdings has provided supplemental disclosures to its definitive proxy statement regarding its pending acquisition by Curium US Holdings LLC. The...

Lantheus Drops 20% on Curium Deal Jitters — Can a New Cancer Drug Save a Merger in Limbo?

Lantheus Drops 20% on Curium Deal Jitters — Can a New Cancer Drug Save a Merger in Limbo?

Shares of Lantheus Holdings cratered 20.5% to $79.49 on September 23, after Curium withdrew and refiled its antitrust paperwork with federal regulators — a...

🔴 Lantheus is trading 20.51% down today in after-hours trading as Curium deal faces renewed FTC scrutiny

Lantheus is trading 20.51% down now at $79.49 in after-hours trading amid renewed antitrust scrutiny of its planned Curium acquisition. - Curium withdrew and...

Lantheus Refiles HSR Notice for Curium Merger, Extending FTC Review Period

Lantheus Refiles HSR Notice for Curium Merger, Extending FTC Review Period

Lantheus Holdings provided a regulatory update on its pending acquisition by Curium US Holdings LLC, announcing the withdrawal and subsequent refiling of its...

Farallon Capital Reveals New $424M Stake in Lantheus Holdings

Hedge fund Farallon Capital Management established a new position in Lantheus Holdings (LNTH), a radiopharmaceutical company, according to its latest quarterly...

Lantheus Lands a New Alzheimer's Tool, but Does It Matter When the Company Is Already Headed for a Buyout?

Lantheus Lands a New Alzheimer's Tool, but Does It Matter When the Company Is Already Headed for a Buyout?

Shares of Lantheus Holdings barely budged — trading at $100.91, virtually flat — after the company announced FDA approval of a new brain-imaging agent that...

Lantheus Wins FDA Approval for TAUKLARIFY to Detect Alzheimer’s Tau Pathology

Lantheus Wins FDA Approval for TAUKLARIFY to Detect Alzheimer’s Tau Pathology

Lantheus Holdings received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a new radiodiagnostic agent. The agent identifies tau neurofibrillary...

Lantheus Holdings Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026

Consensus Q2 2026 revenue is pegged at $362.4 million with an EPS of $1.11, while the stock currently trades at $102.64, trailing the average analyst price...

Lantheus to be Acquired by Curium for $102.50 Per Share Plus Contingent Payments

Lantheus to be Acquired by Curium for $102.50 Per Share Plus Contingent Payments

Lantheus Holdings, Inc. (LNTH) has entered into a definitive merger agreement to be acquired by Curium US Holdings LLC. Under the terms of the agreement,...

Lantheus Announces FDA Acceptance of Alzheimer's Imaging Agent NDA

Lantheus Holdings announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for MK-6240. MK-6240 is an...

Lantheus Faces Continued Scrutiny as Investor Lawsuit Deadline Looms

On October 14, 2025, Lantheus Holdings Inc. (LNTH) was prominently featured in financial news due to multiple law firms issuing reminders to investors about...